Mibelle Biochemistry Expands Portfolio with Mirexus Inc. Asset Deal

Mibelle Biochemistry has successfully completed an asset deal with Mirexus Inc., a Canadian company that offers a sustainable plant-derived glycogen (phytoglycogen) called PhytoSpherix for use in personal care products. 

 

The agreement was effective Oct. 1. Terms of the deal were not disclosed.

 

The deal strengthens Mibelle Biochemistry’s active ingredient portfolio and enhances its position as a developer and manufacturer of unique, high-quality active ingredients for the cosmetic and nutraceutical industry. The new assets also drive Mibelle Biochemistry’s sustainable innovation efforts by further aligning the portfolio with the rising demand for natural and sustainable ingredients.

 

The branded products, PhytoSpherix, EnerZea, Adveen and Susttain, are fully integrated in the portfolio of Mibelle Biochemistry and are available for purchase at Mibelle Biochemistry.

 

“I am very excited about this asset deal, as we had been looking around for quite a while to find a perfect target, matching our philosophy ‘inspired by nature – realized by science’ and similarly fitting smoothly into our existing product portfolio,” said Cornelia Schürch, managing director at Mibelle Biochemistry. “PhytoSpherix is finally fulfilling both requirements.”

 

“All of us at Mirexus are thrilled to find the ideal home for our technology at Mibelle Biochemistry,” added Phil Whiting, president & CEO of Mirexus Biotechnologies Inc. “The deep knowledge and capabilities of Mibelle will enable the growth of this technology beyond what Mirexus could do on its own. We look forward to seeing the continued expansion of our technology under Mibelle’s experienced leadership.”